Overview

Muscle Impact of Treating Osteoporosis

Status:
Not yet recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity). There is strong evidence of overlap between the pathophysiology of osteoporosis and sarcopenia (muscle-bone crosstalk). This research plan will further explore the relationship between bone and muscle, and provide new information about effect of osteoporosis medications on muscle health in older adults who are under treatment for osteoporosis.
Phase:
Phase 4
Details
Lead Sponsor:
Nami Safai Haeri
Collaborators:
National Institute on Aging (NIA)
The Claude D. Pepper Older Americans Independence Centers
Treatments:
Denosumab
Zoledronic Acid